At least 17 medical facilities in Georgia have advertised the experimental drug, which Lilly is still studying and has been moving to crack down on.
Recap by typeshit. Full story at Inc. on MSN.
HHS is proposing temporary enforcement priorities and side effect reporting for compounded peptides, with more specifics in Becker's rundown.
Bloomberg reports the Kennedy plan to widen peptide access comes with a side effect reporting rule for compounding pharmacies.
A Facebook user explains that compounded GLP-1 versions were allowed during the branded drug shortage and flags what that means for people still using them.
Sahpra reports about 600 fake medicine complaints this year, and new compounding rules aren't due until early next year, which industry head Stavros Nicolaou calls too late.
Centre Daily Times looks at how peptides taken by mouth can get past the gut intact and reach specific spots in the body, a key hurdle for pill versions of these drugs.
About half of Australia's roughly 500,000 GLP-1 users pay privately, A$200 to $700 a month, and the authors argue cost hits those with the most obesity hardest.
Loading…